New Deals, Modalities In Sights In Japan After Relatively Quiet 2022

Digital Tools, Cell/Gene Therapies Key Areas?

After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.  

Glasses
A look back and ahead at the Japan pharma commercial landscape in 2022-23 • Source: Shutterstock

More from Global Vision

More from In Vivo